Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study [PDF]
PLoS ONE, 2018 Cancer and factor V Leiden mutation are both risk factors for venous thromboembolism (VTE). Cancer critically increases the thrombotic risk whereas Factor V Leiden is the most common pro-thrombotic mutation.
Cecile Tromeur +2 more
exaly +2 more sources
Mechanisms of the Factor V Leiden Paradox [PDF]
Arteriosclerosis, Thrombosis, and Vascular Biology, 2008 Objective— Carriers of the factor V Leiden mutation (FVL-carriers) have a substantially increased risk of deep venous thrombosis (DVT), whereas the risk of pulmonary embolism (PE) is only mildly increased compared with noncarriers.
Ton Lisman, C J M Doggen
exaly +5 more sources
Factor V Leiden Mutation in Cerebrovascular Disease
Clinical and Applied Thrombosis/Hemostasis, 2005 Several studies indicate a high prevalence of factor V Leiden mutation as the most frequent coagulation defect found in patients with venous thrombosis. The relationship between this mutation and cerebrovascular disease has not been established in adults.
Buyru, N +3 more
openaire +3 more sources
Factor V Leiden Mutation and Stroke
Pediatric Neurology Briefs, 2001 The association of the factor V Leiden mutation and cerebrovascular disorder (CVD) in children is reviewed and the clinical features of 8 children with cerebral palsy (CP) and the Leiden mutation are described from the National Institute of Neurological ...
J Gordon Millichap
doaj +2 more sources
FACTOR V LEIDEN AND THROMBOEMBOLISM [PDF]
Basrah Journal of Surgery, 2004 Zuhair Al-Barazanchi
doaj +2 more sources
SV-IV Peptide1–16 reduces coagulant power in normal Factor V and Factor V Leiden [PDF]
Journal of Translational Medicine, 2007 Native Factor V is an anticoagulant, but when activated by thrombin, Factor X or platelet proteases, it becomes a procoagulant. Due to these double properties, Factor V plays a crucial role in the regulation of coagulation/anticoagulation balance. Factor
Ferrazzi Paola +6 more
doaj +2 more sources
A Case-Control Study of Factor V Leiden G1691A and MTHFR A1298C Polymorphisms and Clinical Outcomes in Patients With COVID-19. [PDF]
Immun Inflamm DisÇıralıoğlu H +7 more
europepmc +3 more sources
First report of bilateral avascular necrosis (AVN) of the femoral heads in a patient with dual factor V deficiency and factor V Leiden mutation: A unique coagulopathy intersection with therapeutic insights. [PDF]
Clin Med (Lond)Li W, Li H, Dou X, Zheng D, Liu C.
europepmc +3 more sources
Factor V Leiden and Cardiopulmonary Bypass
The Journal of ExtraCorporeal Technology, 2015 We present a case of a patient with factor V Leiden with an antithrombin III activity of 67% who received a successful aortic valve replacement supported by cardiopulmonary bypass (CPB). A safe level of anticoagulation was achieved by monitoring activated clotting time (ACT) and heparin concentration ensuring adequate anticoagulation throughout the ...
Victor, Uppal +5 more
openaire +3 more sources
Retraction: The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia. [PDF]
CureusSayed WS +4 more
europepmc +3 more sources